Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Gastroesophageal Junction Adenocarcinoma”

89 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 89 results

Testing effectiveness (Phase 2)Study completedNCT01498289
What this trial is testing

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionEsophageal CancerGastric Cancer
SWOG Cancer Research Network 213
Testing effectiveness (Phase 2)Study completedNCT00045526
What this trial is testing

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Who this might be right for
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionRecurrent Esophageal Cancer+3 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Study completedNCT00381706
What this trial is testing

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal Cancer
Alliance for Clinical Trials in Oncology 245
Testing effectiveness (Phase 2)Study completedNCT00607594
What this trial is testing

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachRecurrent Gastric Cancer+4 more
National Cancer Institute (NCI) 21
Not applicableNot Yet RecruitingNCT07455422
What this trial is testing

Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

Who this might be right for
Barrett EsophagusBarrett Esophagus AdenocarcinomaAdenocarcinoma - GEJ+2 more
University Hospital, Antwerp 266
Testing effectiveness (Phase 2)Study completedNCT00096031
What this trial is testing

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal Cancer
SWOG Cancer Research Network 63
Testing effectiveness (Phase 2)Looking for participantsNCT07546812
What this trial is testing

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Who this might be right for
HER2-negativeGastroesophageal JunctionEsophageal Adenocarcinoma+1 more
Gilead Sciences 120
Testing effectiveness (Phase 2)Study completedNCT01260701
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Gastric AdenocarcinomaGastric Intestinal Type Adenocarcinoma+2 more
National Cancer Institute (NCI) 75
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Early research (Phase 1)Study completedNCT00635596
What this trial is testing

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Who this might be right for
Solid Tumors
Amgen Research (Munich) GmbH 65
Testing effectiveness (Phase 2)Study completedNCT03918499
What this trial is testing

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8+15 more
City of Hope Medical Center 9
Testing effectiveness (Phase 2)Study completedNCT00061932
What this trial is testing

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the Stomach+5 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT03196232
What this trial is testing

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Esophageal Carcinoma+4 more
George Albert Fisher 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT01142388
What this trial is testing

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Metastatic Esophageal AdenocarcinomaMetastatic Esophageal Squamous Cell CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+5 more
National Cancer Institute (NCI) 94
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Testing effectiveness (Phase 2)Looking for participantsNCT07622940
What this trial is testing

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Who this might be right for
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech 36
Testing effectiveness (Phase 2)Looking for participantsNCT07127822
What this trial is testing

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMSI-H Cancer
Peking University 106
Testing effectiveness (Phase 2)Study completedNCT00032123
What this trial is testing

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastric Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT00268346
What this trial is testing

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal Cancer
Case Comprehensive Cancer Center 58
Next Page